CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1

What Was Tested

This randomized controlled trial paper looks at Cagrilintide and CagriSema (Cagrilintide + Semaglutide) in the context of low blood pressure and orthostatic hypotension.

URL: https://www.clinicaltrials.gov; Unique identifier: NCT05567796.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Cagrilintide and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Cagrilintide, so expectations could not easily colour the readings.

Some participants received a placebo instead of Cagrilintide, giving a reference point.

Secondary and post hoc analyses evaluated the antihypertensive effect from REDEFINE 1, focusing on CagriSema and placebo groups, by subgroup/category, including baseline body mass index, the presence of hypertension or resistant hypertension at baseline, and concomitant changes in the use of antihypertensive medications.

What Was Measured

PubMed files the paper under topics including Hypertension, Obesity, Blood Pressure, Antihypertensive Agents, Overweight, Glucagon-Like Peptides and Body Mass Index.

The authors tagged it with the keywords cardiovascular diseases and islet amyloid polypeptide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Cagrilintide and CagriSema (Cagrilintide + Semaglutide) in people with low blood pressure and orthostatic hypotension.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Hypertension (Dallas, Tex. : 1979)), a journal based in United States.

More context: the Cagrilintide compound page and the CagriSema (Cagrilintide + Semaglutide) compound page, Low blood pressure and orthostatic hypotension research.